ATRA

Atara Biotherapeutics (ATRA)

About Atara Biotherapeutics (ATRA)

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Details

Daily high
$11.47
Daily low
$9.86
Price at open
$10.43
52 Week High
$39.50
52 Week Low
$6.50
Market cap
65.7M
Dividend yield
0.00%
Volume
152,323
Avg. volume
78,077
P/E ratio
-.44

Atara Biotherapeutics News

Details

Daily high
$11.47
Daily low
$9.86
Price at open
$10.43
52 Week High
$39.50
52 Week Low
$6.50
Market cap
65.7M
Dividend yield
0.00%
Volume
152,323
Avg. volume
78,077
P/E ratio
-.44